The effect of multimodal therapy on time to progression (TTP) and overall survival (OS) in unresectable locally advanced non-metastatic pancreatic cancer (LANMPC)
Y Al-Farhat, J Hadjiev, D Kelemen, K Hideghéti, T Csere, K Stefanits, M Eleméry, Ö Horváth, I Repa, O Ésik · Zeitschrift für Gastroenterologie · 2005 · Heft 05
Bibliografische Angaben
Zusammenfassung
Background: Pancreatic cancer is difficult to treat and almost impossible to screen for. Surgical resection offers the best possibility for cure, however, only 15–20% of patients are diagnosed with the disease at a resectable stage. We initiated a multimodal regimen to investigate the TTP and OS for patients with LANMPC. Methods: Between January 2003 and January 2005 21 unresectable patients were treated with LANMPC (T4, N Gem-5-FU (1000mg/m2 Gemcitabine and 500mg/m2 5-Fluorouracil) weekly for 13 weeks followed by chemoradiotherapy (CH-RT) in 17th week: total dose: 45Gy, 1.8Gy/day, 5 days a week, 5 weeks, and co…
